Abstract 2092P
Background
Breast cancer tops the list of cancer types prevalent in Algeria, with more than 14,000 new cases recorded each year, of which a significant rate appears before the age of 40. it is aggressive and requires the use of chemotherapy known to be associated with immediate and long-term toxicities, which may affect the quality of life of cancer survivors. One of the chemotherapy-related long-term toxicities among premenopausal patients is hormonal changes with ovarian failure, chemotherapy-related amenorrhoea (CRA) and early menopause witch may lead to bone loss.The objectives were to evaluate bone mineral density (BMD) and to determine potential associated factors for bone loss among young premenopausal patients after adjuvant chemotherapy.
Methods
We included premenopausal Algerian aged <45 years who had received adjuvant chemotherapy. At study entry, background demographics, cancer characteristics and menstrual history were collected; BMD was measured by DXA in trabecular and cortical sites. Factors associated with reduced BMD and fracture risk were analyzed.
Results
A total of 83 patients were evaluated.The median age at the time of diagnosis of breast cancer is 37 years old, while the age at entry into the study is 43 years old. The median BMDs for femoral neck (FN) was 1.02 g/cm2 and lumbar spine (LS) 0.95 g/cm2; 37.2% had abnormal Z-scores (defined as ≤–1) and 44.7% had osteopenia/osteoporosis of either FN or LS. On multivariate analyses, factors that were identified correlated with bone loss (low BMD) are: young age at cancer diagnosis (OR [95% CI] = 2.103 [1.091–3.181), low Vitamine D level (OR = 2.254 [1.541–4.637]), low BMI (OR = 2.56 [1.599–2.907]), longer interval since last adjuvant treatment (OR for LS: 2.217 [1.250–4.357]), and having received adjuvant tamoxifen (OR = 1.752 [1.243–3.841]).
Conclusions
This study highlights that bone loss is prevelent condition in early breast cancer survivors who are on or after chemotherapy. About 44.7% of early breast cancer survivors found to have bone loss .To prevent bone fracture; certain factors associated with this condition deserve to be detected and corrected.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
HCA Hospital University of Algiers Algeria.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2116P - Preoperative body mass index, waist circumference, and mortality after major cancer surgery: A nationwide cohort study in South Korea
Presenter: Jiwon Yoon
Session: Poster session 06
2117P - Dietary patterns and clinical outcomes in patients with lung cancer: What needs to change
Presenter: Imanuely Borchardt
Session: Poster session 06
2118P - Refeeding syndrome: A prospective analysis in adults admitted to an oncology hospital
Presenter: Filipe Gonçalves
Session: Poster session 06
2119P - The prognostic impact of nutritional assessment and scores in advanced gastric cancer
Presenter: Sara Torresan
Session: Poster session 06
2120P - Nutritional deficiency post gastric cancer surgery
Presenter: Abay Makishev
Session: Poster session 06
2121P - Association between nutritional status and adverse events in gastrointestinal cancer patients undergoing outpatient chemotherapy in Japan
Presenter: Naoko Sato
Session: Poster session 06
2122P - Clinical significance of oncology patients’ nutritional status assessment
Presenter: Efthymios Kostaridis
Session: Poster session 06
2123P - Value of immuno-nutritional scores in the prognosis of hospitalised patients with lung cancer
Presenter: Jesús López
Session: Poster session 06
2124P - The impact of NUTRItional status at first medical oncology visit ON Clinical Outcomes: The NUTRIONCO study
Presenter: Maurizio Muscaritoli
Session: Poster session 06
2125P - Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study
Presenter: Alessio Cortellini
Session: Poster session 06